

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-15 (canceled).

Claim 16 (currently amended): An aerosol,
which is produced from a solution consisting of:
one or more solubilized active material(s),
a propellant consisting of a mixture of HFA 227 and HFA 134a, and ethanol as a
cosolvent;
wherein the ratio of HFA 227:HFA 134a ranges from 10:90 to 90:10 and said ratio is
selected to produce [[an]] aerosol particles having an MMAD (mass median aerodynamic
diameter) greater than 2 μ m, wherein at least 40% of said aerosol is composed of fine particles
having a diameter of less than 4.7 μ m;
wherein said aerosol particles have ~~has~~ an MMAD greater than 2 μ m, and
wherein at least 40% of said aerosol is composed of fine particles having a diameter
of less than 4.7 μ m.

Claim 17 (currently amended): The aerosol of Claim 16, wherein the percentage of
particles having a diameter of less than 4.7 μ m in said aerosol is >50%.

Claims 18-27 (canceled).

Claim 28 (previously presented): The aerosol of Claim 16, wherein the active material comprises a β 2 agonist.

Claim 29 (previously presented): The aerosol of Claim 16, wherein the active material comprises a corticosteroid.

Claim 30 (previously presented): The aerosol of Claim 16, wherein the active material comprises an anti-cholinergic drug.

Claim 31 (previously presented): An aerosol inhaler that produces the aerosol of Claim 16.

Claim 32 (previously presented): An aerosol inhaler that produces the aerosol of Claim 17.

Claim 33 (previously presented): An aerosol inhaler that produces the aerosol of Claim 16, wherein at least a portion of the internal surface(s) of said aerosol inhaler comprise stainless steel, anodized aluminum or an inert organic coating.